Recro Pharma Reports Second Quarter 2015 Financial Results
August 14, 2015 16:05 ET
|
Societal CDMO, Inc.
‒ Closed Acquisition of Phase III-Ready IV/IM Meloxicam, Cash Flow Positive Manufacturing/Formulation Business from Alkermes ‒
‒ Announced Positive Phase II Dex-IN Results...
Recro Pharma Announces Additional Information for Phase II Clinical Trial of Dex-IN
July 24, 2015 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., July 24, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma Appoints Scott Rizzo as General Manager
July 20, 2015 16:01 ET
|
Societal CDMO, Inc.
MALVERN, Pa., July 20, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma Announces Positive Top-Line Results for Phase II Clinical Trial of Dex-IN
July 17, 2015 08:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., July 17, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma Completes $16 Million Private Financing
July 07, 2015 17:01 ET
|
Societal CDMO, Inc.
MALVERN, Pa., July 7, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma Announces $16 Million Financing
July 01, 2015 09:15 ET
|
Societal CDMO, Inc.
MALVERN, Pa., July 1, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma to Present at the Jefferies 2015 Global Healthcare Conference
May 28, 2015 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., May 28, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma Reports First Quarter 2015 Financial Results
May 12, 2015 18:03 ET
|
Societal CDMO, Inc.
Strengthened Company with Acquisition of Phase III-Ready IV/IM Meloxicam, Cash Flow Positive Manufacturing/Formulation Business from Alkermes
Encouraging Dex-IN Interim Analysis Results Support...
Recro Pharma Completes Acquisition of IV/IM Meloxicam and cGMP Manufacturing Facility and Business Unit From Alkermes
April 13, 2015 07:00 ET
|
Societal CDMO, Inc.
- Transformative Acquisition Diversifies Recro Pharma's Development Risk with Second, Complementary Acute Pain Product
- Phase III-Ready, Long-Acting Injectable Meloxicam Has...
Recro Pharma Announces Update on On-Going Phase II Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
April 09, 2015 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., April 9, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute...